Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The acquisition involves all issued and outstanding common shares of Repare Therapeutics Inc.
XenoTherapeutics, Inc. and Xeno Acquisition Corp. will acquire Repare Therapeutics Inc. through a statutory plan of arrangement
Shareholder Approval
99.76% of the votes cast by shareholders approved the special resolution for the acquisition.
Compensation Approval
99.34% of shareholders approved the compensation for the named executive officers related to the acquisition.
Voluntary Liquidation
99.75% of shareholders approved the voluntary liquidation and dissolution of Repare Therapeutics Inc. in case the arrangement is terminated.
- The approval of the acquisition marks a significant step in the strategic direction of Repare Therapeutics Inc.
- The completion of the arrangement is expected to occur on or about January 28, 2026, pending court approval and satisfaction of closing conditions.
The acquisition approval by Repare Therapeutics Inc. shareholders paves the way for a new chapter in the company's journey with XenoTherapeutics, Inc.